Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0036341 (
schizophrenia
)
60,220
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
DISC1
is expressed in the hippocampus and has been identified as a possible genetic risk factor for both
schizophrenia
and bipolar disorder. These psychiatric illnesses are associated with impaired learning and memory. This study investigates the association of variation in
DISC1
with cognitive function on the same general mental ability test (Moray House Test) at age 11 and age 79, and cognitive change between ages 11 and 79, in 425 people from the Lothian Birth Cohort 1921 (LBC1921). Tests of memory, non-verbal reasoning and executive function were also administered at age 79. The effect of genotype at a non-synonymous single nucleotide polymorphism in exon 11, rs821616, was studied. There was no direct effect of
DISC1
genotype on any cognitive measure. However, there was a significant
DISC1
genotype by sex interaction on Moray House Test scores at age 79, both before and after adjustment for cognitive ability at age 11 (p = 0.034 and 0.043, respectively). Women homozygous for the Cys allele had significantly lower cognitive ability scores than men at age 79, p = 0.003. Variation in
DISC1
may therefore affect cognitive aging especially in women.
...
PMID:Association between genotype at an exonic SNP in DISC1 and normal cognitive aging. 1605 97
We recently reported an association between
DISC1
and
schizophrenia
, schizoaffective disorder, and bipolar disorder. Convergent evidence suggests that
DISC1
has a direct effect on central nervous system functioning. However, there is a paucity of data investigating the effects of
DISC1
on neurocognition. Thus, we analyzed the relationship between five single-nucleotide polymorphisms that influenced risk for
schizophrenia
in our previous study and neurocognition in 250 patients with
schizophrenia
.
DISC1
genotype was related to neurocognitive performance on measures of rapid visual search and verbal working memory, when controlling for age and premorbid intellectual capacity, and explained 3%-4% of the variance. These data suggest that
DISC1
is associated with neurocognitive functioning in
schizophrenia
.
...
PMID:DISC1 and neurocognitive function in schizophrenia. 1605 47
We have previously reported evidence of linkage and association between markers on 1q42 and
schizophrenia
in a study sample of 498 multiply affected Finnish nuclear families, leading to the recent identification of four significantly associated haplotypes that specifically implicate the Translin-Associated Factor X (TRAX) and Disrupted in
Schizophrenia
1 and 2 (
DISC1
and DISC2) genes in the genetic etiology of
schizophrenia
. Previously, the DISC genes were found to be disrupted by a balanced translocation (1;11)(q42.1;q14.3) that cosegregated with
schizophrenia
and related disorders in a large Scottish pedigree. Interestingly, we also reported earlier suggestive linkage between endophenotypic quantitative traits of visual and verbal memory and microsatellite markers in close proximity to TRAX/DISC, on 1q41. Here, we tested if the identified allelic haplotypes of TRAX/DISC would be associated with visual and/or verbal memory function impairments that are known to aggregate with
schizophrenia
in families. One haplotype of
DISC1
, HEP3, displayed association with poorer performance on tests assessing short-term visual memory and attention. Analysis of affected and unaffected offspring separately revealed that both samples contribute to the observed association to visual working memory. These results provide genetic support to the view that the
DISC1
gene contributes to sensitivity to
schizophrenia
and associated disturbances and affects short-term visual memory functions. This finding should stimulate studies aiming at the molecular characterization of how the specific alleles of
DISC1
affect the visual memory functions and eventually participates in the development of
schizophrenia
.
...
PMID:A haplotype within the DISC1 gene is associated with visual memory functions in families with a high density of schizophrenia. 1610 88
It has been conventional for psychiatric research, including the search for predisposing genes, to proceed under the assumption that
schizophrenia
and bipolar disorder are separate disease entities with different underlying etiologies. These represent Emil Kraepelin's traditional dichotomous classification of the so-called "functional" psychoses and form the basis of modern diagnostic practice. However, findings emerging from many fields of psychiatric research do not fit well with this model. In particular, the pattern of findings emerging from genetic studies shows increasing evidence for an overlap in genetic susceptibility across the traditional classification categories-including association findings at DAOA(G72), DTNBP1 (dysbindin), COMT, BDNF,
DISC1
, and NRG1. The emerging evidence suggests the possibility of relatively specific relationships between genotype and psychopathology. For example,
DISC1
and NRG1 may confer susceptibility to a form of illness with mixed features of
schizophrenia
and mania. The elucidation of genotype-phenotype relationships is at an early stage, but current findings highlight the need to consider alternative approaches to classification and conceptualization for psychiatric research rather than continuing to rely heavily on the traditional Kraepelinian dichotomy. As psychosis susceptibility genes are identified and characterized over the next few years, this will have a major impact on our understanding of disease pathophysiology and will lead to changes in classification and the clinical practice of psychiatry.
...
PMID:Genes for schizophrenia and bipolar disorder? Implications for psychiatric nosology. 1631 75
Impressive advances in the last decade have been made in the genetics and neuroscience of neuropsychiatric illness. Synergies between complex genetics, elaboration of intermediate phenotypes (Egan et al. (2004)
Schizophrenia
. London: Blackwell) and novel applications in neuroimaging (Bookheimer et al. (2000) N Engl J Med, 343, 450-456) are revealing the effects of positively associated disease alleles on aspects of neurological function. Genes such as NRG-1,
DISC1
, RGS4, COMT, PRODH, DTNBP1, G72, DAAO, GRM3 (Harrison and Weinberger (2005) Mol Psychiatry, 10, 40-68) and others have been implicated in
schizophrenia
along with 5-HTTPR (Ogilvie et al. (1996) Lancet, 347, 731-733; Caspi et al. (2003) Science, 301, 386-389) and BDNF (Geller et al. (2004) Am J Psychiatry, 161, 1698-1700) in affective disorders. As the genetics and complex neurocircuits of these and disorders are being untangled, parallel applications in pharmacogenomics and gene-based drug metabolism are shaping a drive for personalized medicine. Genetic research and pharmacogenomics suggest that the subcategorization of individuals based on various sets of susceptibility alleles will make the treatment of neuropsychiatric and other illnesses more predictable and effective.
...
PMID:Psychiatric genetics--the new era: genetic research and some clinical implications. 1636 81
Disrupted-In-
Schizophrenia
(
DISC1
) is a leading candidate
schizophrenia
susceptibility gene. Here, we describe a deletion variant in mDisc1 specific to the 129S6/SvEv strain that introduces a termination codon at exon 7, abolishes production of the full-length protein, and impairs working memory performance when transferred to the C57BL/6J genetic background. Our findings provide insights into how
DISC1
variation contributes to
schizophrenia
susceptibility in humans and the behavioral divergence between 129S6/SvEv and C57BL/6J mouse strains and have implications for modeling psychiatric diseases in mice.
...
PMID:Disc1 is mutated in the 129S6/SvEv strain and modulates working memory in mice. 1648 69
Recent important advancements in genomic research have opened the way to new strategies for public health management. One of these questions pertains to how individual genetic variation may be associated with individual variability in response to drug treatment. The field of pharmacogenetics may have a profound impact on treatment of complex psychiatric disorders like
schizophrenia
. However, pharmacogenetic studies in
schizophrenia
have produced conflicting results. The first studies examined potential associations between clinical response and drug receptor genes. Subsequent studies have tried to use more objective phenotypes still in association with drug receptor genes. More recently, other studies have sought the association between putative causative or modifier genes and intermediate phenotypes. Thus, conflicting results may be at least in part explained by variability and choice of the phenotype, by choice of candidate genes, or by the relatively little knowledge about the neurobiology of this disorder. We propose that choosing intermediate phenotypes that allow in vivo measurement of specific neuronal functions may be of great help in reducing several of the potential confounds intrinsic to clinical measurements. Functional neuroimaging is ideally suited to address several of these potential confounds, and it may represent a powerful strategy to investigate the relationship between behavior, brain function, genes, and individual variability in the response to treatment with antipsychotic drugs in
schizophrenia
. Preliminary evidence with potential susceptilibity genes such as COMT,
DISC1
, and GRM3 support these assumptions.
...
PMID:Imaging genomics and response to treatment with antipsychotics in schizophrenia. 1649 Apr 18
DISC1
has been identified as a
schizophrenia
susceptibility gene based on linkage and SNP association studies and clinical data suggesting that risk SNPs impact on hippocampal structure and function. In cell and animal models, C-terminus-truncated
DISC1
disrupts intracellular transport, neural architecture and migration, perhaps because it fails to interact with binding partners involved in neuronal differentiation such as fasciculation and elongation protein zeta-1 (FEZ1), platelet-activating factor acetylhydrolase, isoform Ib, PAFAH1B1 or lissencephaly 1 protein (LIS1) and nuclear distribution element-like (NUDEL). We hypothesized that altered expression of
DISC1
and/or its molecular partners may underlie its pathogenic role in
schizophrenia
and explain its genetic association. We examined the expression of
DISC1
and these selected binding partners as well as reelin, a protein in a related signaling pathway, in the hippocampus and dorsolateral prefrontal cortex of postmortem human brain patients with
schizophrenia
and controls. We found no difference in the expression of
DISC1
or reelin mRNA in
schizophrenia
and no association with previously identified risk
DISC1
SNPs. However, the expression of NUDEL, FEZ1 and LIS1 was each significantly reduced in the brain tissue from patients with
schizophrenia
and expression of each showed association with high-risk
DISC1
polymorphisms. Although, many other
DISC1
binding partners still need to be investigated, these data implicate genetically linked abnormalities in the
DISC1
molecular pathway in the pathophysiology of
schizophrenia
.
...
PMID:Expression of DISC1 binding partners is reduced in schizophrenia and associated with DISC1 SNPs. 1651 Apr 95
Though Kraepelin's century-old division of major mental illness into mood disorder and
schizophrenia
remains in place, debate abounds over the most appropriate classification. Although these arguments previously rested solely on clinical grounds, they now are rooted in genetics and neurobiology. This article reviews evidence from the fields of genetic epidemiology, linkage, association, cytogenetics, and gene expression. Taken together, these data suggest some overlap in the genes that predispose to bipolar disorder and
schizophrenia
. One gene, DAOA (D-amino acid oxidase activator, also known as G72), has been repeatedly implicated as an overlap gene, while
DISC1
and others may constitute additional shared susceptibility genes. Further, some evidence implicates syndromes of co-occurring mood and psychotic symptoms in association with the putative risk alleles in overlap genes. From a nosologic perspective, the existence of overlap genes, coupled with the genotype-phenotype correlations discovered to date, supports the reality of the much debated schizoaffective disorder. Potential non-overlap syndromes--such as nonpsychotic bipolar disorder or cyclothymic temperament, on the one hand, and negative symptoms or the deficit syndrome, on the other--could turn out to have their own unique genetic determinants. If genotypes are to be the anchor points of a clinically useful system of classification, they must ultimately be shown to inform prognosis, treatment, and prevention. No gene variants have yet met these tests in bipolar disorder or
schizophrenia
.
...
PMID:Carving chaos: genetics and the classification of mood and psychotic syndromes. 1660 72
Cognitive impairment is a prominent and debilitating feature of
schizophrenia
. Genetic predisposition likely accounts for a large proportion of these cognitive deficits. Direct associations between candidate genes and cognitive dysfunction have been difficult to establish, however, largely due to the subtle effects of these genes on observable behavior. Neuroimaging techniques can provide a sensitive means to bridge the neurobiology of genes and behavior. Here we illustrate the use of neuroimaging-genetics paradigms to elaborate the relationship between genes and cognitive dysfunction in
schizophrenia
. After reviewing principles important for the selection of genes, neuroimaging techniques, and subjects, we describe how imaging-genetics investigations have helped clarify the contribution of five candidate genes (COMT, GRM3, G72,
DISC1
, and BDNF) to cognitive deficits in
schizophrenia
. The potential of this approach for improving patient care will depend on its ability to predict outcomes with greater accuracy and sensitivity than current clinical measures.
...
PMID:Neuroimaging-genetic paradigms: a new approach to investigate the pathophysiology and treatment of cognitive deficits in schizophrenia. 1660 74
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>